Cancer News and Research

Latest Cancer News and Research

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Cancer experts call for global action on diesel fumes

Diesel exhaust fumes have been classified as carcinogenic to humans by the International Agency for Research on Cancer, following a week-long meeting of international experts.

14 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Laparoscopy technique lights up invisible metastases

Fluorescence laparoscopy could be the way forward for cancer surgery and staging, say researchers writing in the Archives of Surgery.

14 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

First inventory of microbial diversity in the world's oceans

The landmark publication this week of a "map" of the bacterial make-up of healthy humans has deep roots in an unexpected place: the ocean.

14 Jun 2012

African-American women with low SES more likely to develop obesity

Socioeconomic status across one's lifetime is related to weight gain and risk of obesity in African American women, according to a new study led by researchers from the Slone Epidemiology Center at Boston University. These findings currently appear online in the journal Ethnicity & Disease.

14 Jun 2012

ABL to perform process development and cGMP manufacturing of recombinant scuPA

Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung.

14 Jun 2012

WHO agency classifies diesel exhaust as 'carcinogenic'

The International Agency for Research on Cancer (IARC), the WHO's cancer arm, on Tuesday announced it has reclassified diesel engine exhaust from "probably carcinogenic" to "carcinogenic," the U.N. News Centre reports, noting the decision came "after a week-long meeting of international experts, and the agency based its decision on sufficient evidence that exposure is associated with an increased risk for lung cancer."

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Use, overuse of imaging tests adds about $100 billion to U.S. medical bills

The use of diagnostic imaging has nearly tripled since the mid-1990s, according to a new study, raising questions about whether the benefits outweigh the risks of increased radiation exposure.

14 Jun 2012

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Study shows how cisplatin prevents clumping of hSOD1 linked to ALS

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting.

14 Jun 2012

Mayo Clinic urologists recommend personalized approach for prostate cancer screening

There is a lot of conflicting advice about prostate cancer screening. A recent U.S. Preventative Services Task Force recommendation against prostate-specific antigen testing, regardless of age, has added to men's confusion about how to protect themselves from a cancer that hits roughly 240,000 new patients every year and claims 28,000 lives.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Multimedia intervention effective in changing patients' perceptions, attitudes toward clinical trials

Seeking ways to change cancer patients' perceptions and negative attitudes towards clinical trials participation, researchers at Moffitt Cancer Center conducted a study offering two different kinds of intervention to two groups of adults with cancer who had not previously been asked to participate in clinical trials. They found a multimedia psychoeducational intervention to be more effective in changing patients' perceptions and negative attitudes toward clinical trials than standard educational literature.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012